Cargando…

P1007: PHASE 2, OPEN-LABEL, MULTICENTER, SINGLE-ARM STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ROPEGINTERFERON ALFA-2B IN JAPANESE PATIENTS WITH POLYCYTHEMIA VERA

Detalles Bibliográficos
Autores principales:	Kirito, K., Edahiro, Y., Ohishi, K., Gotoh, A., Takenaka, K., Shibayama, H., Shimizu, T., Usuki, K., Shimoda, K., Ito, M., VanWart, S. A., Zagrijtschuk, O., Qin, A., Kawase, H., Miyachi, N., Sato, T., Komatsu, N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429268/ http://dx.doi.org/10.1097/01.HS9.0000846896.29524.36

Ejemplares similares

Cost–effectiveness of ropeginterferon alfa-2b-njft for the treatment of polycythemia vera
por: Gerds, Aaron T, et al.
Publicado: (2023)

Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b
por: Kiladjian, Jean-Jacques, et al.
Publicado: (2022)

A Case Report of Ropeginterferon Alfa-2b for Polycythemia Vera during Pregnancy
por: Bang, Su-Yeon, et al.
Publicado: (2023)

P1060: THE IMPACT OF POLYCYTHEMIA VERA ON DAILY LIVING, AND SYMPTOM AND TREATMENT PERCEPTION GAPS BETWEEN PATIENTS AND PHYSICIANS: RESULTS OF A CROSS-SECTIONAL SURVEY IN JAPAN
por: Edahiro, Yoko, et al.
Publicado: (2023)

Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment
por: Gisslinger, Heinz, et al.
Publicado: (2023)

A new dosing regimen of ropeginterferon alfa-2b is highly effective and tolerable: findings from a phase 2 study in Chinese patients with polycythemia vera
por: Jin, Jie, et al.
Publicado: (2023)

P1042: COMPARISON OF THE RESPONSE TO ROPEGINTERFERON ALFA-2B IN HYDROXYUREA NAÏVE VERSUS RESISTANCE/INTOLERANCE POLYCYTHEMIA VERA: THE KOREAN SINGLE-ARM, OPEN-LABEL MULTICENTER STUDY
por: Lee, Sung-Eun, et al.
Publicado: (2023)

Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo
por: Verger, Emmanuelle, et al.
Publicado: (2018)

Ropeginterferon Alfa-2b: Efficacy and Safety in Different Age Groups
por: Gisslinger, Heinz, et al.
Publicado: (2020)

Tumor Lysis Syndrome after the Administration of Ruxolitinib in a Patient with Post-polycythemia Vera Myelofibrosis
por: Koshiishi, Megumi, et al.
Publicado: (2017)

Recent advances in prognostication and treatment of polycythemia vera
por: Marcellino, Bridget K, et al.
Publicado: (2021)

Real world experience with ropeginterferon alpha-2b (Besremi) in essential thrombocythaemia and polycythaemia vera following exposure to pegylated interferon alfa-2a (Pegasys)
por: Okikiolu, Jumoke, et al.
Publicado: (2022)

Immunomodulatory and direct activities of ropeginterferon alfa‐2b on cancer cells in mouse models of leukemia
por: Sakatoku, Kazuki, et al.
Publicado: (2022)

Isolated Cilioretinal Artery Occlusion as an Initial Manifestation of Polycythemia Vera
por: Elasri, Fouad, et al.
Publicado: (2010)

JAK2 Negative Polycythemia Vera
por: Geetha, J P, et al.
Publicado: (2010)

Ruxolitinib in Myelofibrosis and Polycythemia Vera
por: Wolfe, Leah
Publicado: (2016)

Thromboembolic events in polycythemia vera
por: Griesshammer, Martin, et al.
Publicado: (2019)

Genetic Background of Polycythemia Vera
por: Regimbeau, Mathilde, et al.
Publicado: (2022)

Population Pharmacokinetics of Ropeginterferon Alfa-2b: A Comparison Between Healthy Caucasian and Chinese Subjects
por: Zhu, Min, et al.
Publicado: (2021)

Differential cytokine network profile in polycythemia vera and secondary polycythemia
por: Cacemiro, Maira da Costa, et al.
Publicado: (2020)

Lemierre’s Syndrome in an Elderly Female Patient with Polycythemia Vera: Does Polycythemia Vera Predispose to Lemierre’s Syndrome?
por: Kundal, Sanchit V., et al.
Publicado: (2021)

P1036: VOLUMETRIC SPLENOMEGALY IN PATIENTS WITH POLYCYTHEMIA VERA
por: Lee, M.-W., et al.
Publicado: (2022)

Polycythemia Vera Presenting as Cardiac Arrest: Novel Management Strategies
por: Davis, Mark I., et al.
Publicado: (2019)

Polycythemia vera presenting with bilateral papilledema
por: Nithyanandam, Suneetha
Publicado: (2009)

Electrocardiographic Findings in Patients with Polycythemia Vera
por: Kayrak, Mehmet, et al.
Publicado: (2011)

Hypercalcemia in a Patient with Polycythemia Vera
por: Bae, Eun Hui, et al.
Publicado: (2012)

Chorea disclosing a polycythemia vera
por: Liu, Guidong, et al.
Publicado: (2014)

An oncolytic parasite to treat polycythemia vera
por: Rizvi, Syeda Taliya, et al.
Publicado: (2015)

Bilateral adrenal hemorrhage in polycythemia vera
por: Bhandari, Shruti, et al.
Publicado: (2016)

Therapy of polycythemia vera: is it time to change?
por: Passamonti, Francesco, et al.
Publicado: (2017)

Polycythemia vera treatment algorithm 2018
por: Tefferi, Ayalew, et al.
Publicado: (2018)

When hemolysis masks polycythemia vera
por: Derrieux, Coralie, et al.
Publicado: (2019)

Takotsubo Cardiomyopathy Associated with Polycythemia Vera
por: Basnet, Sijan, et al.
Publicado: (2018)

Is there a gender effect in polycythemia vera?
por: Palandri, Francesca, et al.
Publicado: (2020)

Polycythemia Vera Presenting as Hemorrhagic Stroke
por: Balagopal, Krishnan, et al.
Publicado: (2021)

Volumetric Splenomegaly in Patients With Polycythemia Vera
por: Lee, Myung-Won, et al.
Publicado: (2022)

Polycythemia Vera: Thinking Beyond the Hematocrit
por: Waggoner, Matthew
Publicado: (2023)

Ropeginterferon alfa‐2b in patients with genotype 1 chronic hepatitis C: Pharmacokinetics, safety, and preliminary efficacy
por: Lin, Hsien‐Hong, et al.
Publicado: (2021)

Clinical Experience with Ropeginterferon Alfa-2b in the Off-Label Use for the Treatment of COVID-19 Patients in Taiwan
por: Chen, Kuan-Yuan, et al.
Publicado: (2021)

Rapidly progressed aortic stenosis in a patient with previous diagnosis of polycythemia vera and post‐polycythemia vera myelofibrosis
por: Kiso, Shohei, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_nup02fffcu115oh94lqgt8ki6a